NM_004168.4(SDHA):c.718G>A (p.Glu240Lys) AND multiple conditions

Clinical significance:Uncertain significance (Last evaluated: Dec 20, 2019)

Review status:1 star out of maximum of 4 stars

criteria provided, single submitter

Based on:
1 submission [Details]
Record status:

Allele description [Variation Report for NM_004168.4(SDHA):c.718G>A (p.Glu240Lys)]

NM_004168.4(SDHA):c.718G>A (p.Glu240Lys)

SDHA:succinate dehydrogenase complex flavoprotein subunit A [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Genomic location:
Preferred name:
NM_004168.4(SDHA):c.718G>A (p.Glu240Lys)
  • NC_000005.10:g.228281G>A
  • NG_012339.1:g.15041G>A
  • NM_001294332.1:c.574G>A
  • NM_001330758.1:c.718G>A
  • NM_004168.4:c.718G>AMANE SELECT
  • NP_001281261.1:p.Glu192Lys
  • NP_001317687.1:p.Glu240Lys
  • NP_004159.2:p.Glu240Lys
  • LRG_315t1:c.718G>A
  • LRG_315:g.15041G>A
  • LRG_315p1:p.Glu240Lys
  • NC_000005.9:g.228396G>A
  • NM_004168.3:c.718G>A
Protein change:
Molecular consequence:
  • NM_001294332.1:c.574G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001330758.1:c.718G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_004168.4:c.718G>A - missense variant - [Sequence Ontology: SO:0001583]


Mitochondrial complex II deficiency, nuclear type 1
Mitochondrial complex II deficiency; Complex 2 mitochondrial respiratory chain deficiency; Succinate CoQ reductase deficiency; See all synonyms [MedGen]
MONDO: MONDO:0100294; MedGen: C1855008; Orphanet: 3208; OMIM: 252011
Paragangliomas 5 (PGL5)
MONDO: MONDO:0013602; MedGen: C3279992; Orphanet: 29072; OMIM: 614165

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
SCV001213731Invitaecriteria provided, single submitter
Uncertain significance
(Dec 20, 2019)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing



Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240-242.

PubMed [citation]

Details of each submission

From Invitae, SCV001213731.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)


This sequence change replaces glutamic acid with lysine at codon 240 of the SDHA protein (p.Glu240Lys). The glutamic acid residue is highly conserved and there is a small physicochemical difference between glutamic acid and lysine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with SDHA-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: Deleterious; PolyPhen-2: Probably Damaging; Align-GVGD: Class C1). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. 5

OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Jul 24, 2021

Support Center